Patents by Inventor Nicholas A. Meanwell

Nicholas A. Meanwell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • C17-ARYL SUBSTITUTED BETULINIC ACID ANALOGS
    Publication number: 20170305962
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.
    Type: Application
    Filed: November 12, 2015
    Publication date: October 26, 2017
    Applicant: ViiV Healthcare UK (No.5) Limited
    Inventors: Jie CHEN, Yan CHEN, Nicholas A. MEANWELL, Alicia REGUEIRO-REN, NY SIN, Sing-Yuen SIT
  • Hepatitis C virus inhibitors
    Patent number: 9770439
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: September 26, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Piyasena Hewawasam, Omar D. Lopez, Yong Tu, Alan Xiangdong Wang, Ningning Xu, John F. Kadow, Nicholas A. Meanwell, Samayamunthula Venkata Satya Arun Kumar Gupta, Indasi J. Gopi Kumar, Suresh Kumar Ponugupati, Makonen Belema
  • Hepatitis C virus inhibitors
    Patent number: 9758487
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: September 12, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Gan Wang, Lawrence G. Hamann
  • IMMUNOMODULATORS
    Publication number: 20170252432
    Abstract: The present disclosure provides novel macrocyclic compounds which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: March 1, 2017
    Publication date: September 7, 2017
    Inventors: Martin Patrick Allen, Eric P. Gillis, David R. Langley, Michael Matthew Miller, Eric Mull, Li-Qiang Sun, Kap-Sun Yeung, Katharine A. Grant-Young, Nicholas A. Meanwell, Paul Michael
  • BETULINIC ACID DERIVATIVES WITH HIV MATURATION INHIBITORY ACTIVITY
    Publication number: 20170204133
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivaties that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III: These compounds are useful for the treatment of HIV and AIDS.
    Type: Application
    Filed: June 17, 2015
    Publication date: July 20, 2017
    Inventors: Alicia REGUEIRO-REN, Animesh GOSWAMI, Zhiwei GUO, Thomas P. TULLY, Jacob SWIDORSKI, Zheng LIU, Nicholas A. MEANWELL
  • Tricyclic alkene derivatives as HIV attachment inhibitors
    Patent number: 9655888
    Abstract: Compounds of Formula (I), including pharmaceutically acceptable salts thereof: wherein A is selected from the group consisting of: and wherein Z is: are useful as HIV attachment inhibitors.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: May 23, 2017
    Assignee: ViiV Healthcare UK (No.5) Limited
    Inventors: Tao Wang, John F. Kadow, Nicholas A. Meanwell, Zhongxing Zhang, Zhiwei Yin, Edward H. Ruediger, Clint A. James, Daniel H. Deon
  • 2-keto amide derivatives as HIV attachment inhibitors
    Patent number: 9586957
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof: I useful as HIV attachment inhibitors.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: March 7, 2017
    Assignee: ViiV Healthcare UK (No.5) Limited
    Inventors: Tao Wang, Zhiwei Yin, Zhongxing Zhang, John A. Bender, Barry L. Johnson, John F. Kadow, Nicholas A. Meanwell
  • TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY
    Publication number: 20170056420
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: with X selected from C4-8 cycloalkyl, C4-8 cycloalkenyl, C4-9 spirocycloalkyl, C4-9 spirocycloalkenyl, C4-8 oxacycloalkyl, C4-8 dioxacycloalkyl, C6-8 oxacycloalkenyl, C6-8 dioxacycloalkenyl, C6 cyclodialkenyl, C6 oxacyclodialkenyl, C6-9 oxaspirocycloalkyl and C6-9 oxaspirocycloalkenyl ring, such that X is substituted with A, wherein A is —C1-6 alkyl-halo. These compounds are useful for the treatment of HIV and AIDS.
    Type: Application
    Filed: November 7, 2016
    Publication date: March 2, 2017
    Inventors: Sing-Yuen SIT, Yan CHEN, Jie CHEN, Jacob SWIDORSKI, Brian Lee VENABLES, Ny SIN, Nicholas A. MEANWELL, Alicia REGUEIRO-REN, Richard A. HARTZ, Li XU, Zheng LIU
  • Hepatitis C virus inhibitors
    Patent number: 9546160
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: January 17, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Qi Chen, Omar D. Lopez, John A. Bender, Gan Wang, Van N. Nguyen, John F. Kadow, Nicholas A. Meanwell, Makonen Belema
  • Hepatitis C virus inhibitors
    Patent number: 9527885
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: December 27, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sheldon Hiebert, Ramkumar Rajamani, Li-Qiang Sun, Eric Mull, Eric P. Gillis, Michael S. Bowsher, Qian Zhao, Nicholas A. Meanwell, Kishore V. Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, P.V.K. Suresh Babu, Paul Michael Scola
  • Triterpenoids with HIV maturation inhibitory activity
    Patent number: 9527882
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: with X selected from C4-8 cycloalkyl, C4-8 cycloalkenyl, C4-9 spirocycloalkyl, C4-9 spirocycloalkenyl, C4-8 oxacycloalkyl, C4-8 dioxacycloalkyl, C6-8 oxacycloalkenyl, C6-8 dioxacycloalkenyl, C6 cyclodialkenyl, C6 oxacyclodialkenyl, C6-9 oxaspirocycloalkyl and C6-9 oxaspirocycloalkenyl ring, such that X is substituted with A, wherein A is —C1-6 alkyl-halo. These compounds are useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: December 27, 2016
    Assignee: ViiV Healthcare UK (No.4) Limited
    Inventors: Sing-Yuen Sit, Yan Chen, Jie Chen, Jacob Swidorski, Brian Lee Venables, Ny Sin, Nicholas A. Meanwell, Alicia Regueiro-Ren, Richard A. Hartz, Li Xu, Zheng Liu
  • SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS
    Publication number: 20160361328
    Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.
    Type: Application
    Filed: August 29, 2016
    Publication date: December 15, 2016
    Inventors: Yasutsugu UEDA, Timothy P. CONNOLLY, John F. KADOW, Nicholas A. MEANWELL, Tao WANG, Chung-Pin H. CHEN, Kap-Sun YEUNG, Zhongxing ZHANG, David Kenneth LEAHY, Shawn K. PACK, Nachimuthu SOUNDARARAJAN, Pierre SIRARD, Kathia LEVESQUE, Dominique THORAVAL
  • Piperidine amide derivatives as HIV attachment inhibitors
    Patent number: 9505752
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof: formula (I): wherein A is selected from the group consisting of: formula (II) and wherein Z is selected from the group consisting of: formula (III): and. are useful as HIV attachment inhibitors.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: November 29, 2016
    Assignee: ViiV Healthcare UK (No. 5) Limited
    Inventors: Tao Wang, Zhongxing Zhang, John F. Kadow, Nicholas A. Meanwell, Edward H. Ruediger, Clint A. James, Daniel H. Deon, David J. Carini, Barry L. Johnson
  • Hepatitis C Virus Inhibitors
    Publication number: 20160311778
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Application
    Filed: June 28, 2016
    Publication date: October 27, 2016
    Inventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Gan Wang, Lawrence G. Hamann
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20160257645
    Abstract: Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth: Formula: (I)
    Type: Application
    Filed: October 23, 2014
    Publication date: September 8, 2016
    Inventors: Annapurna Pendri, Guo Li, John A. Bender, Zhong Yang, Alan Xiangdong Wang, Brett R. Beno, Robert A. Fridell, Makonen Belema, Nicholas A. Meanwell, Robert G. Gentles
  • SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS
    Publication number: 20160207918
    Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives having the Formula I: wherein Q is These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
    Type: Application
    Filed: March 16, 2016
    Publication date: July 21, 2016
    Inventors: Tao Wang, Zhongxing Zhang, Nicholas A. Meanwell, John F. Kadow, Zhiwei Yin, Qiufen May Xue, Alicia Regueiro-Ren, John D. Matiskella, Yasutsugu Ueda
  • HEPATITIS C VIRUS INHIBITORS
    Publication number: 20160199355
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Application
    Filed: March 11, 2016
    Publication date: July 14, 2016
    Inventors: PIYASENA HEWAWASAM, JOHN F. KADOW, OMAR D. LOPEZ, NICHOLAS A. MEANWELL, YONG TU, ALAN XIANGDONG WANG, NINGNING XU, SAMAYAMUNTHULA VENKATA SATYA ARUN KUMAR GUPTA, POTHUKANURI SRINIVASU, INDASI GOPI KUMAR, PONUGUPATI SURESH KUMAR, MAKONEN BELEMA, ROBERT A. FRIDELL, MIN GAO, JULIE A. LEMM, DONALD R. O'BOYLE, II, JIN-HUA SUN, CHUNFU WANG, YING-KAI WANG
  • Combinations of Hepatitis C Virus Inhibitors
    Publication number: 20160158200
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Application
    Filed: July 9, 2013
    Publication date: June 9, 2016
    Inventors: Piyasena Hewawasam, Omar D. Lopez, Yong Tu, Alan Xiangdong Wang, Ningning Xu, John F. Kadow, Nicholas A. Meanwell, Samayamunthula Venkata Satya Arun Kumar Gupta, Indasi J. Gopi Kumar, Suresh Kumar Punugupati, Makonen Belema
  • PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES
    Publication number: 20160152615
    Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
    Type: Application
    Filed: February 4, 2016
    Publication date: June 2, 2016
    Inventors: TAO WANG, Zhongxing Zhang, Nicholas A. Meanwell, John F. Kadow, Zhiwei Yin, Qiufen May Xue, Alicia Regueiro-Ren, John D. Matiskella, Yasutsugu Ueda
  • COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY
    Publication number: 20160151387
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 and C-3 modified triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III: These compounds are useful for the treatment of HIV and AIDS.
    Type: Application
    Filed: February 4, 2016
    Publication date: June 2, 2016
    Inventors: Alicia Regueiro-Ren, Zheng Liu, Jacob Swidorski, Ny Sin, Brian Lee Venables, Sing-Yuen Sit, Yan Chen, Jie Chen, Nicholas A. Meanwell